EXSCIENTIA PLC (EXAI) Stock News

USA - NASDAQ:EXAI - US30223G1022 - ADR

4.84 USD

+0.15 (+3.2%)

Last: 11/19/2024, 8:18:05 PM

4.85 USD

+0.01 (+0.21%)

After Hours: 11/19/2024, 8:18:05 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EXAI Latest News, Press Relases and Analysis

All

Press Releases

10 months ago - By: Recursion Pharmaceuticals, Inc. - Mentions: RXRX

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

a year ago - By: Exscientia plc

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

a year ago - By: BusinessInsider

News Image

EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024

a year ago - By: Viva Biotech Holdings

News Image

Latest Updates of Viva Biotech's Portfolio Companies

a year ago - By: Exscientia plc

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

a year ago - By: Benzinga - Mentions: BIOR NXL RHE XCUR ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

a year ago - By: Exscientia plc

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

a year ago - By: Yahoo Finance - Mentions: RXRX NVDA

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

a year ago - By: The Motley Fool - Mentions: RXRX

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

a year ago - By: InvestorPlace

EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024

a year ago - By: Exscientia plc

Exscientia Business Update for Second Quarter and First Half 2024

a year ago - By: FN Media Group LLC - Mentions: AVAI RXRX TWST IQV

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

a year ago - By: The Motley Fool - Mentions: RXRX

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

a year ago - By: Benzinga - Mentions: RXRX

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

a year ago - By: Recursion Pharmaceuticals, Inc. - Mentions: RXRX

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

a year ago - By: Exscientia plc

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

a year ago - By: Exscientia plc

Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery

a year ago - By: InvestorPlace - Mentions: CHPT VRDN AMGN

3 Small-Cap Stocks With Explosive 2X Growth Potential

a year ago - By: Faruqi & Faruqi, LLP

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia

a year ago - By: The Schall Law Firm

EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm

a year ago - By: Gross Law Firm

EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline

a year ago - By: The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)

a year ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines - EXAI

a year ago - By: The Rosen Law Firm PA

EXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI

a year ago - By: THE ROSEN LAW FIRM, P. A.

EXAI DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action - EXAI